Mission
At Glucotrack, our mission is to become a leader in diabetes management by developing and commercializing innovative, novel, and cost-effective technologies that address multiple categories within the diabetes market.
Paul V Goode, PhD
Paul is a highly accomplished medical device professional with extensive experience in all areas of operations and product development, from initial concept to global commercialization. Prior to his appointment as President & CEO of Glucotrack, Paul served as a member of Integrity’s Board of Directors.
During his over twenty-year medical device career, Paul has spent considerable time working with innovative diabetes management technologies, including as Vice President of R&D at MetaCure, a neurostimulator device for Type 2 diabetes; Director of Engineering and Algorithm Development at DexCom, a global continuous glucose monitoring company; and, as Senior Engineer at MiniMed, Inc., maker of integrated insulin pump and continuous glucose sensor systems, prior to its acquisition by Medtronic.
Paul received his BS, MS and PhD degrees from North Carolina State University, and is a named inventor on over 150 issued patents, including over 100 relating to DexCom’s continuous glucose sensing technology.
JP Thrower
James brings over 15 years of diverse medical device experience as a seasoned engineering and global product development leader with a track record of successfully leading large healthcare technology-focused projects across multiple geographies from prototype design through clinical trials and FDA submissions. His engineering expertise spans electrical, mechanical, software, algorithm design, and artificial intelligence. At Integrity, he will migrate innovations from Integrity’s advanced technologies team in Israel through the product development and regulatory processes in preparation for manufacturing and commercial launch.
James joins the Company from Sterling Medical Devices, a medical device design and development firm where he focused on product development, software and system development, risk assessment and FDA quality assurance. Previously, he served in leadership roles at Mindray DS USA Inc., the U.S. subsidiary of Shenzhen exchange listed Mindray Bio-Medical Electronics Co., including as Director of Product Development and Director of Next Generation Monitoring.
Prior to that, James served as Senior Software and Electrical Engineer at continuous glucose monitoring company, DexCom. James earned his bachelor’s degree in both Electrical Engineering and Computer Engineering, as well as his PhD and MSc in Electrical Engineering from North Carolina State University. He is a published author in numerous industry publications and is a named inventor on over 120 patents.
Mark Tapsak, PhD
Mark brings over 25 years of experience in the diabetes industry as a medical device research scientist, focused on polymer synthesis, polymer characterization, medical device design and intellectual property. At GlucoTrack, he will lead the recently announced R&D program for a novel implantable continuous glucose monitoring system (CGM) for those with Type 1 diabetes.
Mark joins the Company from Diabetic Health, Inc., a developer of specialty coatings utilized in continuous glucose monitoring sensors and insulin infusion sets, where he served as President. Over his career, Mark held senior positions at several diabetes management companies including as Senior Scientist at Dexcom, Inc. where he oversaw sensor electrochemical performance, biointerface design and membrane technology, and as Senior Chemist at Medtronic, Inc. He has also taught as a Professor of Chemistry and Biochemistry and served as the Assistant Dean of Science and Technology and as Dean of Graduate Programs and Sponsored Research at Bloomsburg University. He has authored dozens of industry publications with thousands of citations and is a named inventor of 68 patents, of which over 50 are DexCom assigned patents. He received his Bachelor of Educational Studies in Chemistry and Photographic Sciences from St. Cloud State University and his PhD in Polymer Chemistry from the University of Southern California.
Drinda Benjamin
Drinda has 25 years of experience in the medical device industry from diabetes to surgical robotics. She brings extensive diabetes device experience with a focus on the commercialization of health technology. Within diabetes, she has past experiences in product development, strategic marketing, and both upstream and downstream marketing in the areas of blood glucose monitoring, continuous glucose monitoring (CGM), insulin delivery and closed loop systems.
Drinda joins the company from Intuity Medical where she developed and executed commercial strategies for a novel integrated blood glucose monitoring system. Prior to this, she led business development, partnership strategy and closed loop system programs for Senseonics, manufacturer of the 1st implantable CGM launched in the US and Europe. She has also held marketing roles with Abbott Diabetes Care and Medtronic Diabetes.
Drinda has an M.B.A. from Georgetown University’s McDonough School of Business and a Bachelor of Science in Engineering degree from Princeton University.
Vincent Wong
Vincent has extensive experience in life sciences and medical device manufacturing, with expertise in driving product & process risk management activities to support sustainable product launch of Class III active implantable devices. He joins the company from TOMZ Corporation where he served as Chief Quality Officer and led the strategic development and deployment of the Quality and Business Management System at one of the world’s leading high-volume medical device manufacturers and acquired entities. Prior to this, he was responsible for overseeing all corporate Quality functions at Cirtec Medical, including the organization’s Product Development Process, FDA inspections, ISO 13485:2016 transition and establishment of the Corporate Quality Management System across all sites, facilitating the integration of multiple acquisitions and new site launches.
Vincent has both a Master and Bachelor of Science in Biomedical Engineering from the University of Connecticut.
Board of Directors
Allen Danzig has served on our Board since October 31, 2019 and is the Chair of our Nominating, Governance and Compensation Committee. Mr. Danzig most recently served as Vice President, Assistant General Counsel and Assistant Secretary of L3Harris Technologies, Inc., a global aerospace and defense technology contractor, with $17 billion in annual revenue. Prior to its merger with Harris Corporation in June 2019, Mr. Danzig served as Vice President, Assistant General Counsel and Assistant Secretary at L3 Technologies, Inc. where he had been employed since 2006. Prior to his employment at L3, Mr. Danzig served in management positions with Celanese Corporation, a global chemical and specialty materials company, and The Hertz Corporation, one of the world’s largest vehicle and equipment rental companies.
He received his undergraduate degree from Adelphi University and law degree from Pace University School of Law and is a member of the New York State Bar.
Dr. Robert Fischell has served as one of Integrity’s directors since 2010. He also serves on Integrity’s Nominating, Governance and Compensation Committee. Dr. Fischell is an inventor and serial entrepreneur with over 160 issued U.S. patents. Starting in 1959, Dr. Fischell spent over 30 years with the Johns Hopkins University Applied Physics Laboratory, which resulted in 53 patents in both aerospace and biomedical technology. His interests at Johns Hopkins then turned to the invention of new medical devices such as pacemakers and implantable heart defibrillators.
Starting in 1969, Dr. Fischell began the formation of 14 private companies that licensed his patents on medical devices. These companies include Pacesetter Systems, Inc. (purchased by Siemens and now part of St. Jude Medical, Inc.), IsoStent, Inc. (merged with Cordis Company, a Johnson and Johnson Company), NeuroPace, Inc., Neuralieve, Inc., Angel Medical Systems, Inc., and Svelte Medical Systems, Inc. As it relates to diabetes management devices, he was the inventor of the first implantable insulin pump (which became Minimed, which was sold to Medtronic). Dr. Fischell’s honors include Inventor of the Year for the USA in 1984, election to the National Academy of Engineering in 1989, the Distinguished Physics Alumnus Award of the University of Maryland, and several medals for distinguished accomplishments in science, engineering and innovation. In 2004, Discover magazine gave Dr. Fischell their annual Technology for Humanity award. In 2008, Dr. Fischell received the honorary degree of Doctor of Humane Letters from the Johns Hopkins University in recognition of his many lifesaving inventions.
From June 2009 until March 2011, he was a director of InspireMD, Inc. (OTCBB: NSPR), a medical device company focusing on the development and commercialization of its proprietary stent system, MGuard. Dr. Fischell received his BSME degree from Duke University and MS and Sc.D. degrees from the University of Maryland. At the White House on May 16, 2016, President Obama presented to Dr. Fischell the National Medical of Technology and Innovation, the highest award in the USA for achievements in innovative technology.
Luis Malavé brings more than 30 years of leadership experience in the medtech industry, primarily in diabetes management, spanning all company stages, from private startups to large-cap publicly listed companies. He has extensive expertise in product development, operations, marketing, strategic partnerships, and U.S. Food and Drug Administration regulatory strategy.
Luis currently serves as president of EOFLOW Co. Ltd., a company listed on the Korea Stock Exchange that has developed a wearable disposable insulin pump. Prior to that, Malavé was president and CEO of Palyon Medical, maker of an implantable drug-delivery system that spun out from German medical-technology giant Fresenius SE. Prior to Palyon, he spent nearly a decade at insulin pump maker Insulet Corp., including as its senior vice president of Research, Development and Engineering, and as chief operating officer. He also held various senior positions at Medtronic plc and MiniMed, overseeing product development of various diabetes management devices.
Malavé earned his bachelor’s degree in mathematics and computer science from the University of Minnesota, a master’s degree in software engineering from the University of St. Thomas, and an MBA from the University of Maryland.
Shimon Rapps was appointed as a Director of the Company on July 31, 2019. He is also Chair of Integrity’s Audit Committee. Mr. Rapps currently serves as director of private equity and venture investing for a large family office and is the founder of Three Strands Capital Group, a boutique merchant and investment banking advisory firm.
Previously he served as Head of Investment Banking at Andrew Garrett, Inc., a full-service investment bank providing wealth management and corporate advisory services, where he spent 17 years overseeing all of Andrew Garrett’s corporate finance, investment banking and corporate advisory activities. His experience spans equity and debt financings, mergers and acquisitions, private placements and IPO’s. He has extensive expertise with both public and private, emerging growth and middle-market companies, and regularly advises CEO’s, CFO’s and Boards of Directors on matters of corporate governance and strategy.
He holds Series 7, 24, 63, and 66 licenses and is a Certified Public Accountant (inactive). The Board has determined that Mr. Rapps is suited to serve due to his extensive investment banking and public company experience.
Andrew Sycoff has served as a Director of the Company since July 8, 2019, and is a member of the Nominating, Governance and Compensation Committee. Mr. Sycoff is the founder, Chief Executive Officer and Chairman of the Board of Andrew Garrett, Inc., a full-service investment bank providing wealth management and corporate advisory services, for which he has served as CEO and Chairman continuously since 1992. Client sectors include high net worth individuals and early to middle-market stage companies.
Mr. Sycoff holds Series 7 and 24 licenses. Mr. Sycoff has been actively investing in and advising companies for over 25 years and has extensive experience in the areas of securities brokerage, Capital Markets, Corporate Advisory and Mergers & Acquisitions. Mr. Sycoff previously served on the board of Brokerage America and Paragon Industries Corp., an electronics contract manufacturer. The Board has determined that Mr. Sycoff is suited to serve due to his extensive investment banking and public company experience.
Erin Carter brings more than 30 years of executive level finance experience in the medical
device and healthcare industries. In the past decade, she held various senior roles with
Medtronic, most recently serving as Chief Financial Officer and Vice President of Finance for
their $9B Neuroscience Portfolio. In addition, during her tenure at Medtronic she grew the
Gastrointestinal Solutions division from early tech start-up acquisition of $36M in revenue to
$450M in 5 years through organic growth and multiple acquisitions.
Prior to Medtronic, Ms. Carter served as Director of Operations Finance at Boston Scientific and
as VP of Accounting and Reporting at UnitedHealth Group. Early in her career, she served as
Assistant Controller for Arterial Vascular Engineering, where she was instrumental in guiding the
rapid growth of the company from 200 employees to over 4,000 in under three years. During
this time, she managed the integration of two acquisitions and subsequently the company’s sale
and integration to Medtronic. She began her career with Coopers & Lybrand, LLC in San Jose,
California.
Ms. Carter holds a B.S. in Business Administration from California Polytechnic State University
and is a Certified Public Accountant (inactive) in the State of California.
Careers
We are always looking for passionate, talented individuals interested in bringing innovative technologies to the millions of people living with diabetes. If you are interested in joining our team, send your resume and a cover letter to: careers@glucotrack.com.
gluconews
Sign up to our newsletter and be the first to know our latest developments